Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

Incannex Healthcare (Nasdaq: IXHL) says its oral synthetic psilocybin program PSX-001 for Generalized Anxiety Disorder aligns with the White House Executive Order dated April 18, 2026.

Rhea-AI Summary

Incannex Healthcare (Nasdaq: IXHL) says its oral synthetic psilocybin program PSX-001 for Generalized Anxiety Disorder aligns with the White House Executive Order dated April 18, 2026. The company cites Phase 2 results showing a 12.8-point HAM-A reduction vs 3.6 placebo, 44% response and 27% remission in 73 patients.

Incannex reports no serious adverse events, an active U.S. IND, and over $70 million cash with no debt. The Executive Order could speed regulatory pathways but requires Phase 3 success for DEA rescheduling.

Positive

• Phase 2: 12.8-point HAM-A reduction vs 3.6 placebo
• 44% clinically meaningful response rate in treated patients
• 27% remission rate sustained through 11 weeks
• Study population: 73 patients; no serious adverse events
• Balance sheet: over $70 million cash and no debt
• U.S. IND: active

Negative

• Data limited to Phase 2; Phase 3 still required for approval
• Easier regulatory pathway tied to successful Phase 3 and rescheduling
• Phase 2 sample size of 73 may limit broader statistical certainty

Argus Apr 22 session

+8.49% close to close Open Argus

Details

News Market Reaction – IXHL

In the Apr 22 session, IXHL gained 8.49%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +8.5% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +8.5% in the session following this news. A strong positive reaction aligns with the robust Phase 2 efficacy and safety profile of PSX-001, including a 12.8-point HAM-A reduction and 44% response rate, combined with policy support from the Executive Order. Historically, IXHL has shown large moves on capital-raising and partnership news. Investors would still need to weigh past volatility around offerings and the stock’s position 92.43% below its 52-week high when assessing durability.

Key Figures

HAM-A reduction (drug): 12.8-point reduction HAM-A reduction (placebo): 3.6-point reduction Response rate: 44% +5 more

HAM-A reduction (drug)

12.8-point reduction

PSX-001 Phase 2 primary endpoint vs baseline

HAM-A reduction (placebo)

3.6-point reduction

Phase 2 placebo group

Response rate

44%

Clinically meaningful response (≥50% anxiety reduction) with PSX-001

Remission rate

27%

HAM-A ≤7 remission, sustained through 11 weeks

Trial size

73 patients

Completed Phase 2 PSX-001 trial

Global GAD prevalence

280 million people

Estimated worldwide Generalized Anxiety Disorder population

U.S. GAD prevalence

6.8 million

Estimated U.S. Generalized Anxiety Disorder population

Cash balance

over $70 million

Company cash with no debt, as cited in release

Historical Context

5 past events · Latest: Mar 27

5 events

1. Mar 27

   Share repurchase

   24h Move

   -5.0%

   Reactivation of buyback program with cash-rich, debt-free balance sheet.

2. Mar 25

   R&D partnership

   24h Move

   +15.8%

   Partnership with AASM Foundation to support sleep apnea research.

3. Mar 18

   Balance sheet highlight

   24h Move

   -6.7%

   Emphasis on ~$75M cash, no debt, negative enterprise value.

4. Mar 17

   Nasdaq compliance

   24h Move

   +0.0%

   Regained Nasdaq minimum bid price compliance and confirmed listing.

5. Mar 12

   Equity offering

   24h Move

   -48.4%

   Pricing of $10M registered direct offering with additional warrant overhang.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

psilocybin, generalized anxiety disorder, phase 2, ham-a, +3 more

7 terms

psilocybin medical

"PSX-001, our oral synthetic psilocybin therapeutic for Generalized Anxiety Disorder..."

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

generalized anxiety disorder medical

"psilocybin therapeutic for Generalized Anxiety Disorder, is designed for exactly these patients..."

Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.

phase 2 medical

"In Incannex’s completed Phase 2 clinical trial, PSX-001 demonstrated statistically significant..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

ham-a medical

"12.8-point reduction in HAM-A anxiety scores versus 3.6 points for placebo..."

HAM-A (Hamilton Anxiety Rating Scale) is a clinician-administered questionnaire that scores the severity of a person's anxiety by rating common physical and mental symptoms on a standardized scale. Investors watch HAM-A results in clinical trials because clear changes on the scale can indicate whether a treatment effectively reduces anxiety, which influences regulatory approval, market adoption and the commercial value of a therapy—like a ruler showing how much progress a drug achieved.

breakthrough therapy regulatory

"prioritize review of psychedelic compounds with Breakthrough Therapy designations..."

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

right to try regulatory

"create Right to Try pathways for investigational psychedelics..."

A legal pathway that allows seriously ill patients to try unapproved medicines or treatments outside of formal clinical trials when no approved options remain. For investors, it matters because wider access can alter demand, safety data, and public perception of a drug—similar to an emergency exit that lets more people use a product early but also raises the chances of unexpected outcomes that can affect a company’s regulatory path and reputation.

dea rescheduling regulatory

"and initiate DEA rescheduling upon successful Phase 3 completion."

DEA rescheduling is the formal process by which the U.S. Drug Enforcement Administration changes a drug’s classification under federal controlled‑substances law, altering how tightly it is regulated, prescribed, produced and penalized. For investors, rescheduling can open or restrict markets—like moving a product from a locked cabinet to store shelves—affecting sales potential, manufacturing and licensing requirements, regulatory costs, legal exposure and therefore a company’s revenue and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company’s oral synthetic psilocybin program advances within significantly improved regulatory environment

MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, “Accelerating Medical Treatments for Serious Mental Illness.” The Company believes its PSX-001 development program aligns with the goals outlined in the Executive Order and believes the data demonstrated to date, along with a more amenable regulatory environment, may provide significant hope for those suffering from anxiety disorders.

“We agree with the Administration’s recognition that the mental health crisis in America demands a new level of regulatory urgency and scientific ambition,” commented Incannex CEO Joel Latham. ”For years, patients suffering from debilitating anxiety disorders have had limited options, particularly for those who fail first-line treatments. PSX-001, our oral synthetic psilocybin therapeutic for Generalized Anxiety Disorder, is designed for exactly these patients and this Executive Order represents a meaningful step toward ensuring that novel, evidence-based therapies like ours can reach them without unnecessary delay.”

PSX-001: Rigorous Science, Compelling Data, a Clear Path Forward

PSX-001 is an oral, fixed-dose synthetic psilocybin formulation in development for Generalized Anxiety Disorder (GAD), a condition affecting an estimated 280 million people globally and approximately 6.8 million in the United States. In Incannex’s completed Phase 2 clinical trial, PSX-001 demonstrated statistically significant and clinically meaningful improvements across all primary and secondary endpoints:

• 12.8-point reduction in HAM-A anxiety scores versus 3.6 points for placebo (p<0.0001)
• 44% rate of clinically meaningful response (≥50% anxiety reduction) — four times the placebo rate
• 27% remission rate (HAM-A ≤7) — five times the placebo rate, sustained through 11 weeks
• No serious adverse events and a single discontinuation across 73 patients
  
  

The Executive Order’s direction to the FDA to prioritize review of psychedelic compounds with Breakthrough Therapy designations create Right to Try pathways for investigational psychedelics, and initiate DEA rescheduling upon successful Phase 3 completion. The move also addresses systemic barriers that have historically constrained the development and commercialization of this entire therapeutic category. Incannex views these measures as meaningfully reducing regulatory and commercial risk for the psilocybin class broadly.

“This Executive Order underscores what the clinical evidence has been telling us for years, that psilocybin and related compounds represent a genuinely transformative opportunity in mental health,” Mr. Latham continued. “We are well-funded with over $70 million in cash and no debt, our U.S. IND is active, and we believe our Phase 2 data is among the strongest in the oral psilocybin space. We are advancing PSX-001 with urgency and scientific rigor, and we welcome a regulatory environment that shares that sense of urgency.”

About PSX-001

PSX-001 is an investigational oral synthetic psilocybin therapeutic in development for Generalized Anxiety Disorder. Incannex completed a 73-patient Phase 2 clinical trial in Australia in 2025, reporting statistically significant and durable improvements in anxiety, functioning, depression, and quality of life measures. PSX-001 is the first oral synthetic psilocybin therapeutic in development for GAD.

About Incannex Healthcare Inc.

Incannex is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The Company is advancing three clinical-stage product candidates based on evidence-based innovation and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at www.incannex.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to management’s expectations regarding the share repurchase program, expectations regarding use of the Company’s cash on hand, the potential value of the Company’s drug candidates and business, including these values as compared to available cash, opportunities, the strategy, timing and future development of the Company’s drug candidates, the potential value of the Company and its drug candidates and potential shareholder value. When or if used in this communication, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to the Company, its operations or its management, may identify forward-looking statements. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions, and expectations disclosed in, or implied by, the forward-looking statements. These risks and uncertainties, many of which are beyond our control, include: the risk that the Company’s estimates and current projections regarding the sufficiency of its current cash on hand to fund the Company’s planned operations may be incorrect and the Company may use these resources faster than anticipated or suspend the share repurchase program and other risks described in the section entitled "Risk Factors" described in the prospectus supplement and in the Company's annual report on Form 10-K for the fiscal year ended June 30, 2025, filed with the SEC on September 29, 2025, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, which can be obtained on the SEC website at www.sec.gov and are made available on the Company’s website upon their filing with the SEC. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

Investor & Media Contacts
CORE IR
(212) 655-0924
investors@incannex.com
media@incannex.com.au

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Incannex (IXHL) PSX-001 Phase 2 trial results announced April 22, 2026?

PSX-001 showed a 12.8-point HAM-A reduction vs 3.6 for placebo, with 44% response and 27% remission in 73 patients. According to the company, results were statistically significant, clinically meaningful, and sustained through 11 weeks with no serious adverse events.

How does the April 18, 2026 Executive Order affect Incannex (IXHL) PSX-001 development timeline?

The Executive Order could accelerate regulatory review and create Right to Try routes for psychedelics but requires Phase 3 success. According to the company, DEA rescheduling would be initiated only after a successful Phase 3 completion.

What is Incannex's (IXHL) financial position to support PSX-001 development?

Incannex reports being well-funded with over $70 million in cash and no debt, supporting continued development. According to the company, that cash position and an active U.S. IND allow advancement toward Phase 3 with urgency.

Are there safety concerns reported for PSX-001 from the Phase 2 study?

The Phase 2 study reported no serious adverse events and a single discontinuation across 73 patients. According to the company, safety findings were favorable but require larger Phase 3 evaluation for confirmation.

What regulatory steps remain for Incannex (IXHL) to commercialize PSX-001?

Incannex must complete a successful Phase 3 trial and follow FDA review; DEA rescheduling is tied to Phase 3 success. According to the company, the Executive Order reduces some barriers but does not replace pivotal trial requirements.